Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.25%
#3 Bitway Bitway +11.68%
#4 Glidr Glidr +9.69%
#5 Meteora Meteora +9.51%
#6 OPENLOOT OPENLOOT +8.29%
#7 Unit Pump Unit Pump +8.17%
#8 Pump.fun Pump.fun +8.17%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.80%
#10 eCash eCash +7.48%
Coin of the day
PulseChain PulseChain
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Clasificación en acciones #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Precio por acción
$0.55
Última sincronización: 2025-02-11
Capitalización bursátil
$28.90M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Marinus Pharmaceuticals, Inc. (MRNS)

Categoría

Healthcare
Ingresos de Marinus Pharmaceuticals, Inc. (MRNS)
Ingresos en Sep 2024 TTM: $31.47M
Según los últimos informes financieros de Marinus Pharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son $31.47M. En 2022, la empresa obtuvo unos ingresos de $25.48M un aumento con respecto a los ingresos del año 2021, que fueron de $15.35M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Marinus Pharmaceuticals, Inc. desde 2012 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH